An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

NCT02294734 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: GSK2269557
DRUG: Placebo

Sponsor

GlaxoSmithKline